DDIT3 and diffuse large B-cell lymphoma: One study showed addition of ibrutinib to traditional R-CHOP therapy increased event free survival and overall survival of patients under 60 years of age with non-GCB DLBCL, a notable finding as this is the first time addition of an agent to R-CHOP therapy has improved event free and overall survival of patients (Miao et al., 2019; Younes et al., 2019).